Products - Eye conditions | Topic

Guidance
Skip Standards and indicators submenu
Quality standards
Our quality standards set out priority areas for quality improvement. They highlight areas with identified variation in current practice.
View our quality standards
How to use our quality standards
The timeline for developing quality standards
Help us develop quality standards
Selecting and prioritising quality standards topics
About quality standards
Indicators
Our indicators measure outcomes that reflect the quality of care, or processes linked by evidence to improved outcomes.
View list of indicators
Learn about the committee that develops indicators
About indicators
Skip Life sciences submenu
Life Sciences
We offer tailored support to industry during product development. Our expertise can help you build the evidence needed to achieve market access.
View life sciences
Get support from NICE
NICE Advice service
Trusted, unrivalled expertise.
Make an enquiry
Contact us to discuss your requirements.
Innovative Licensing and Access Pathway (ILAP)
Streamlining patient access to safe, financially sustainable and innovative medicines.
Learn how we evaluate technologies
Health technology evaluation and topic selection manuals
Updated manuals for methods, processes and topic selection.
Digital health technologies
Accelerating our efforts to deliver innovation to the health and care system.
Evidence standards framework
Using the best available evidence to develop recommendations that guide decisions in health, public health and social care.
Our guidance programmes
Ensuring new technologies are clinically effective and offer economic value.
Register your product
Non-pharmaceutical
NHS Innovation Service is a clear and simple point of entry for health technologies to access support and national evaluation programmes.
Pharmaceutical
UK PharmaScan is a database of new medicines, indications and formulations in the pharmaceutical pipeline.
Find published and proposed evaluations
Diagnostics
Guidance on measurements and tests used to evaluate a patient's condition.
Medical technologies
Guidance on medical technologies put forward to NICE by manufacturers.
Technology appraisals
Guidance on new and existing medicines and treatments in the NHS.
Highly specialised technologies
Guidance on the use of highly specialised medicines and treatments.
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
Skip About submenu
About
NICE helps practitioners and commissioners get the best care to patients, fast, while ensuring value for the taxpayer.
Explore about
Our programmes
Learn about the information we produce.
Guidance
Advice
Quality standards
Indicators
Digital health
Topic selection
Get involved
Understand how decisions are made:
Attend a committee meeting
Comment on draft guidance:
Guidance in consultation
Be part of a guidance committee:
Join a committee
Help develop our products:
Register as a stakeholder
Putting you at the heart of our work:
Public involvement
What we do
Social care
Life sciences
NICE international
Patient safety
Shared decision making
Into practice
Social care quick guides
Measuring the use of NICE guidance
Resource planner
View all Into practice
Who we are
The board
The NICE strategy 2021 to 2026
Corporate publications
View all Who we are
- Contact us
- Jobs

Showing 48 products

Date | Title

Guidance programme: Technology appraisal guidanceRemove ‘Guidance programme: Technology appraisal guidance’ filter

Abicipar pegol for treating wet age-related macular degeneration ID1533
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Adalimumab and dexamethasone for treating non-infectious uveitis (TA460)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
26 July 2017
Aflibercept for treating choroidal neovascularisation (TA486)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
1 November 2017
Aflibercept for treating diabetic macular oedema (TA346)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 July 2015
Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion (TA409)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 September 2016
Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion (TA305)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
26 February 2014
Aflibercept for untreated diabetic macular oedema [TSID10621]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Aflibercept for untreated retinopathy in babies born preterm TS ID 11943
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Aflibercept solution for injection for treating wet age‑related macular degeneration (TA294)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
24 July 2013
Avacincaptad pegol for treating geographic atrophy caused by age-related macular degeneration [ID6401]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Bevacizumab gamma for treating wet age-related macular degeneration (TA1022)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
4 December 2024
Bimatoprost implant for treating open angle glaucoma or ocular hypertension when topical treatments are unsuitable [ID6180]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Botaretigene sparoparvovec for treating RPGR mutation-associated X-linked retinitis pigmentosa [TSID10592]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Brolucizumab for treating diabetic macular oedema (TA820)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
31 August 2022
Brolucizumab for treating wet age-related macular degeneration (TA672)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
3 February 2021
Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears (TA369)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
16 December 2015
Ciclosporin ophthalmic solution for treating dry eyes after inadequate response to artificial tears [TSID8472]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Dexamethasone intracanalicular insert for treating inflammation and pain after cataract surgery [ID1154]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion (TA229)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 July 2011
Dexamethasone intravitreal implant for treating diabetic macular oedema (TA824)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
14 September 2022
Faricimab for treating diabetic macular oedema (TA799)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
29 June 2022
Faricimab for treating visual impairment caused by macular oedema after retinal vein occlusion (TA1004)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
11 September 2024
Faricimab for treating wet age-related macular degeneration (TA800)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
29 June 2022
Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema (TA953)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
13 March 2024
Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis (TA590)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
31 July 2019
Glaucoma - lerdelimumab (CAT-152) [ID383]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
High-dose aflibercept for treating wet age-related macular degeneration [TSID10590]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Holoclar for treating limbal stem cell deficiency after eye burns (TA467)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
16 August 2017
Idebenone for treating visual impairment in Leber’s hereditary optic neuropathy in people 12 years and over [ID547]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Inebilizumab for treating AQP4-IgG seropositive neuromyelitis optica spectrum disorders [ID6430]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Latanoprost–netarsudil for previously treated primary open-angle glaucoma or ocular hypertension (TA1009)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
2 October 2024
Lenadogene nolparvovec for treating Leber's hereditary optic neuropathy caused by the G11778A ND4 mitochondrial mutation [ID1410]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Low-dose atropine eye drops for treating myopia in people 3 to 14 years [ID6517]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Netarsudil for treating open angle glaucoma or ocular hypertension [ID1078]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
NVK-002 for treating myopia in people 3 to 17 years [TSID11961]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pegcetacoplan for treating geographic atrophy [ID4041]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Polihexanide eye drops for treating acanthamoeba keratitis in people 12 years and over [ID6497]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Port Delivery platform with ranibizumab for treating wet age-related macular degeneration [ID3983]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ranibizumab and pegaptanib for the treatment of age-related macular degeneration (TA155)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
20 May 2024
Published:
27 August 2008
Ranibizumab for treating choroidal neovascularisation associated with pathological myopia (TA298)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
20 May 2024
Published:
27 November 2013
Ranibizumab for treating diabetic macular oedema (TA274)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
26 October 2023
Published:
27 February 2013
Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion (TA283)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
20 May 2024
Published:
22 May 2013
Ranibizumab port delivery system for treating diabetic macular oedema [ID6137]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ravulizumab for treating AQP4 antibody-positive neuromyelitis optica spectrum disorder (terminated appraisal) (TA941)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
20 December 2023
Satralizumab for preventing relapses in neuromyelitis optica spectrum disorders (terminated appraisal) (TA960)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 March 2024
Tebentafusp for treating advanced uveal melanoma (TA1027)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
9 January 2025
Teprotumumab for treating thyroid eye disease [ID6432]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
20 August 2025
Timrepigene emparvovec for treating choroideremia [ID3916]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC

Quality standards

Indicators

Get support from NICE

Learn how we evaluate technologies

Register your product

Find published and proposed evaluations

Our programmes

Get involved

What we do

Into practice

Who we are

Eye conditions Products

Showing 48 products